PDCD1 and neoplasm: Further understanding of the markers of the underlying mechanisms of this tumor may reveal new therapeutic targets for combination therapies based on the blocking of the PD‐1 pathway, as well as the selection of useful markers for patients most likely to respond to these therapies.